Get started
Author

Lacey James

Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia
2020 · Dai Chihara, Evgeny Arons, et al. · Journal of Clinical Oncology · 105
PDF
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
2021 · Kerry A. Rogers, Leslie A. Andritsos, et al. · Blood · 70
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
2021 · Dai Chihara, Evgeny Arons, et al. · Blood Advances · 29
PDF
COVID-19 in patients with classic and variant hairy cell leukemia
2023 · Robert J. Kreitman, Theresa Yu, et al. · Blood Advances · 6
PDF
Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.
2019 · Dai Chihara, Evgeny Arons, et al. · Journal of Clinical Oncology · 5
Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
2022 · Kerry A. Rogers, Eric McLaughlin, et al. · Blood · 4
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia
2025 · Brett Schroeder, Constance Yuan, et al. · Blood · 3
PDF
Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy
2025 · Robert J. Kreitman, Brett Schroeder, et al. · JCO Precision Oncology · 3
PDF
Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant
2019 · Dai Chihara, Evgeny Arons, et al. · Blood · 3
A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia
2024 · Robert J. Kreitman, Hao-Wei Wang, et al. · Blood · 1
PDF
Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox
2024 · Robert J. Kreitman, Constance M. Yuan, et al. · Blood · 1
Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia receiving moxetumomab pasudotox.
2024 · Robert J. Kreitman, Constance Yuan, et al. · Journal of Clinical Oncology · 1
Phase 2 trial of cladribine plus immediate rituximab for 1st-line treatment of hairy cell leukemia – long term follow-up of original and additional patient cohorts
2025 · Robert Kreitman, Hao-Wei Wang, et al. · Blood
PDF
Phase 2 trial of encorafenib plus binimetinib for patients with BRAF V600 mutated relapsed/refractory hairy cell leukemia
2025 · Robert Kreitman, Hao-Wei Wang, et al. · Blood
PDF
COVID-19 vaccination in patients with classic and variant hairy cell leukemia
2024 · Robert J. Kreitman, Lacey James, et al. · Blood Neoplasia
Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.
2021 · Robert J. Kreitman, Maryalice Stetler-Stevenson, et al. · Journal of Clinical Oncology
Works count: 16
Citation count: 231
H-index: 5
I10-index: 3
Year
Topic
Type